# An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

> **NCT06013475** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1375 (actual)

## Conditions studied

- Non-metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Darolutamide (BAY 1841788)
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06013475
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-31
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 1375 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013475, "An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06013475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*